Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes
Pirfenidone: A Novel Anti-Scarring Therapy for Diabetic Nephropathy
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
A PHASE1/PHASE2 clinical study on Diabetes Mellitus and Diabetic Nephropathy, this trial is completed. The trial is conducted by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health (NIH)
- Sharma, Kumar, M.D.
For direct contact, visit the study record on ClinicalTrials.gov .